Subscribe to Search results

The tax tribunal gave a detailed judgment when upholding HMCE in deciding that the sale of recombinant was liable to VAT. It recorded findings of fact that recombinant was "now considered as the treatment of choice by most clinicians and by the Haemophilia Society."

Published on:

The tax tribunal noted that recombinant had the advantages over blood-derived factor concentrate of being available in an unlimited supply, being a renewable source, and having freedom from blood-borne viral contamination. By comparison, purified plasma derived Factor 8 "might contain low levels of viral contamination."

Published on:

A Haemophilia Society Board of Trustees' meeting recorded the unequal availability of recombinant Factor 8 across the UK.

Published on:

The chair of the Haemophilia Society wrote to Stephen Dorrell reiterating the uneven availability of recombinant Factor 8 across the UK.

Published on:

A panel established by the Board of the Newcastle upon Tyne Hospitals NHS Trust recommended to the Board that "it support the universal availability of recombinant Factor VIII. This recommendation should be conveyed to Health Authorities for funding".

Published on:

Graham Barker, director of services and development at the Haemophilia Society, wrote a letter to Alf Morris MP indicating that some health authorities were refusing to pay the additional costs associated with recombinant Factor 8.

Published on:

Graham Barker wrote to Liz Lynne MP drawing attention to the Government's reluctance to adopt the UKHCDO guidelines and highlighting the difference in approach in Scotland where all children with Haemophilia A had been transferred to recombinant plans, by 1997.

Published on:

Jan Wallace described her involvement in Haemophilia Wales' campaign in 1997 which aimed to "ensure all haemophiliacs in Wales received the safest treatment known as Recombinant".

Published on:

Dr Ludlum raised concerns about the inequality of haemophilia care across the UK, in particular that of the very uneven availability of recombinant factor VIII.

Published on:

Concerns were raised at a meeting between the Haemophilia Society and Department of Health that access to recombinant Factor 8 was not equal.

Published on:

Beverley Tumelty set out the role her late brother, Gareth Lewis, played in campaigning for recombinant treatment for haemophiliacs in Wales. He was Chairman of the South Wales Haemophilia Group during this period.

Published on:

An Information Pack produced by the South Wales Haemophilia Group referred to their success in campaigning for Recombinant treatment for all haemophiliacs in Wales.

Published on:

Dr Graham Winyard and Dr Metters sent a memo to Baroness Jay regarding New Variant CJD and Blood.

Published on:

Carol Grayson wrote to Frank Dobson to enquire about plans to roll out recombinant to all patients, but was told in reply that "there are no plans to arrange this centrally" and that "the Department of Health does not accept that the clinical case has been made for the general use of the recombinant product".

Published on:

One man wrote to Tony Blair expressing his concern that his son's haemophilia treatment might revert to human-derived plasma after he reached the age threshold, as well as expressing further concerns about the affordability of recombinant Factor 8.

Published on:

A Health Services Circular (HSC 1998/999) was published. This promulgated the announcement that central funding would be provided to health authorities in order to provide recombinant Factor 8 to new patients as well as patients under the age of 16.

Published on:

The Department of Health published a further Health Services Circular (HSC 1998/147). This document considered specific arrangements for health authorities to submit claims for additional funding to provide recombinant Factor 8.

Published on:

The Secretary of State agreed to the central funding for 1998/1999 of recombinant Factor VIII for new patients and those under 16. This was on what were described as humanitarian (rather than effectiveness grounds).

Published on:

At a meeting of the UKHCDO Executive Committee Dr Ludlam said that Charles Lister had "again informally indicated that funding for [Factor 8] should continue beyond the 16th birthday."

Published on:

Bruce Norval described writing to the Secretary of State "to try and make sure that kids got on to recombinant products as early as possible".

Published on: